SARS-CoV-2

• Surrogate virus neutralisation test (sVNT) for semi-quantitative detection of neutralising antibodies inhibiting the binding of SARS-CoV-2 S1/RBD to ACE2 receptors of the host cells
• Supports the evaluation of the immune response after SARS-CoV-2 infection or vaccination using S1/RBD-based vaccines
• Very high agreement of results compared with a plaque reduction neutralisation test (PRNT50)
• Established ELISA method – suitable for routine laboratory diagnostics, no BSL-3 laboratory required
• Automatable even for high-throughput analysis, results available in approx. 2 hours
• Modelled upon nature: Neutralising antibodies in the sample compete with the host-cell receptor (ACE2) for the binding to S1/RBD in the first incubation step, no preadsorption required
• Multispecies test- application with animal specimen possible for research use only

1. EUROIMMUN Automation Solutions:

EUROLabWorkstation ELISA, Analyzer I, Analyzer I-2P and Sprinter XL

• Automation of the Anti-SARS-CoV-2 ELISA
• Automation of the Anti-SARS-CoV-2 NCP ELISA

For further information on our automation options, please contact our experts of product management for instruments and software.

2. Processing on all common open ELISA platforms

Products may not be licensed in accordance with the laws and regulations in all countries.

Information -
SARS-CoV-2 variants

According to the well-founded assessment of our scientists, it is not to be expected that the SARS-CoV-2 variants Alpha, Beta, Gamma and Delta have any effect on the performance of our test systems. The experimental data is not yet available to make a statement on the possible effects of the Omicron variant.
Find out more here.

Please contact your
local distributor for further information.

• COVID-19 diagnostics with dried capillary blood1.04 MB
• EUROIMMUN product portfolio for COVID-19 diagnostics2.73 MB